API | talarozole

talarozole Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Talarozole was an investigational drug for the treatment of acne, psoriasis and other keratinization disorders. Development for that purpose has been discontinued. However, its effect in increasing retinoic acid is now being investigated in hand osteoarthritis. ^Wikipedia

Chemistry

SMILES: CCC(CC)C(c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1
InChIKey: SNFYYXUGUBUECJ-UHFFFAOYSA-N
Mol. Mass: 377.52
ALogP: 5.66 Partition coefficient
ChEMBL Molecule:
talarozole

More Chemistry

Pharmacology

Mechanism of Action:
- Cytochrome P450 26A1 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

n-(4-(2-ethyl-1-(1h-1,2,4-triazol-1-yl)butyl)phenyl)-2-benzothiazolamine | r115866 | r 115866 | r-115866 | rambazole | talarozole

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Acne Vulgaris (Phase 2)

Inflammation (Phase 1)

Psoriasis (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue